(Q34155719)

31 July 2017

Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review (English)

1 reference

31 July 2017

1 reference

1 reference

Nektaria Makrilia

1

1 reference

31 July 2017

Ekaterini Syrigou

2

1 reference

31 July 2017

Ioannis Kaklamanos

3

1 reference

31 July 2017

Leonidas Manolopoulos

4

1 reference

31 July 2017

Muhammad Wasif Saif

5

1 reference

31 July 2017

20 September 2010

1 reference

31 July 2017

1 reference

31 July 2017

2010

1 reference

31 July 2017

707-718

1 reference

Creative Commons Attribution 3.0 Unported

31 July 2017

start time

20 September 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Translational research in pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Allergic reactions to oxaliplatin in a single institute in Japan

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Hypersensitivity reactions to antineoplastic agents: an overview

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Head and neck cancer in the elderly: an overview on the treatment modalities

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Pancreatic cancer: from molecular pathogenesis to targeted therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Hypersensitivity reactions to oxaliplatin and other antineoplastic agents

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Developments in the treatment of non-small cell lung cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Carboplatin hypersensitivity.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Hypersensitivity Reactions to oxaliplatin: incidence and management.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Hypersensitivity reactions related to oxaliplatin (OHP).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Hypersensitivity Reactions to Chemotherapeutic Drugs

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Hypersensitivity and idiosyncratic reactions to oxaliplatin

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Cytotoxic therapy of gastroenteropancreatic (GEP) tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Weekly dosing of carboplatin increases risk of allergy in children.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Hypersensitivity and cross-reactivity to cisplatin and analogues

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Specific IgE antibodies to platinum salts in sensitized workers

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Structure, Recognition, and Processing of Cisplatin-DNA Adducts.

5 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Antitumour and toxic effects on Wistar rats of two new platinum complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Successful desensitization to oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in Patients with advanced gastrointestinal carcinomas: a phase I dose-finding and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Idiosyncratic reaction after oxaliplatin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Death from anaphylaxis to cisplatin: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Carboplatin hypersensitivity and desensitization in an infant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Hypersensitivity reactions to oxaliplatin: experience in a single institute

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Skin testing and hypersensitivity reactions to oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F207084

Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945654

Diagnosis and management of hypersensitivity reactions caused by oxaliplatin

28 October 2018

1 reference

12 December 2020

Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital

1 reference

12 December 2020

Immunohemolytic anemia following oxaliplatin administration

1 reference

12 December 2020

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy

1 reference

12 December 2020

Life-threatening carboplatin hypersensitivity during conditioning for autologous PBSC transplantation: successful rechallenge after desensitization

1 reference

12 December 2020

Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy

1 reference

12 December 2020

Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions

1 reference

12 December 2020

Oxaliplatin hypersensitivity: case report and successful repeat desensitization

1 reference

12 December 2020

A modified, prolonged desensitization protocol in carboplatin allergy

1 reference

12 December 2020

Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma

1 reference

12 December 2020

Usefulness of skin testing with platinum salts to demonstrate lack of cross-reactivity between carboplatin and cisplatin

1 reference

12 December 2020

Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses

1 reference

12 December 2020

Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts

1 reference

12 December 2020

Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens

1 reference

12 December 2020

Safety and efficacy of repeated monthly carboplatin desensitization

1 reference

12 December 2020

Successful carboplatin desensitization in patients with proven carboplatin allergy

1 reference

12 December 2020

Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity

1 reference

12 December 2020

Hypersensitivity and idiosyncratic reactions to oxaliplatin

1 reference

12 December 2020

Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity

1 reference

12 December 2020

Hypersensitivity reactions to carboplatin

1 reference

12 December 2020

Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study

1 reference

12 December 2020

Anaphylaxis after oxaliplatin

1 reference

12 December 2020

Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer

1 reference

12 December 2020

Severe anaphylactic reactions to oxaliplatin

1 reference

12 December 2020

Clinical features of hypersensitivity reactions to carboplatin

1 reference

12 December 2020

Serious delayed hypersensitivity reaction to oxaliplatin

1 reference

12 December 2020

Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?

1 reference

12 December 2020

Diagnostic and predictive value of skin testing in platinum salt hypersensitivity

1 reference

12 December 2020

Identifiers

DOI

10.1155/2010/207084

1 reference

31 July 2017

1 reference

31 July 2017

1 reference